CJC-1295 (W/O DAC)
CJC-1295 (W/O DAC)
CJC-1295 (W/O DAC) — Formulation Overview
CJC-1295 Without DAC — also referred to as Modified GRF 1-29 (Mod GRF 1-29) — is a 29-amino acid synthetic analog of growth hormone–releasing hormone (GHRH). The defining characteristic of this formulation is the absence of the Drug Affinity Complex (DAC): the lysine-maleimide side chain present in CJC-1295 (With DAC) that facilitates covalent binding to serum albumin.
Without the DAC moiety, this peptide does not bind to albumin. The result is a short plasma half-life of approximately 30 minutes and a sharp, pulsatile release profile — making it the preferred formulation for researchers studying acute, pulse-mimicking GH secretion events rather than sustained, steady-state hormone elevation.
Without DAC vs. With DAC — Formulation Comparison
| Property | CJC-1295 Without DAC (Mod GRF 1-29) | CJC-1295 With DAC |
|---|---|---|
| Albumin Binding | None | Yes — covalent bond via DAC moiety |
| Approximate Half-Life | ~30 minutes | ~6–8 days |
| GH Release Pattern | Pulsatile (acute, short-duration) | Sustained / continuous elevation |
| Dosing Frequency (Research) | Multiple administrations per study session | Single or infrequent dosing |
| Primary Research Use Case | Pulse-mimicking GH secretion studies; short-window PK modeling | Prolonged steady-state GH studies; long-duration experiments |
| Also Known As | Mod GRF 1-29, Modified GRF 1-29 | CJC-1295 DAC, CJC-1295 with DAC |
Research Applications
In controlled laboratory environments, researchers utilize CJC-1295 (Without DAC) to investigate:
- Pulsatile GH secretion mechanics — modeling natural episodic GH release patterns in preclinical subjects
- Short-term GHRH receptor activation — examining acute receptor binding, downstream signaling, and cellular response windows
- Comparative pharmacokinetic studies — contrasting rapid-clearance versus long-acting GHRH analog profiles side by side
- Hormonal regulatory feedback — studying somatostatin and GH axis feedback mechanisms in short-window experimental designs
Preparation & Handling
Supplied as a lyophilized (freeze-dried) powder. Reconstitution and handling should follow standard laboratory aseptic protocols:
- Reconstitute with bacteriostatic water or appropriate sterile solvent per your laboratory protocol
- Store lyophilized powder in a cool, dry, light-protected environment prior to reconstitution
- Refrigerate after reconstitution; use within your protocol's established stability window
- For extended storage of reconstituted material, freeze at approximately –20°C and avoid repeated freeze-thaw cycles
- Handle under aseptic conditions throughout to preserve compound integrity and purity
⚠️ Research Use Only
This product is strictly intended for in vitro and preclinical research purposes only. It is not approved by the FDA or any regulatory authority for human or veterinary use, consumption, or therapeutic application. Not for human administration. For laboratory research use exclusively.